Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Multiple Myeloma 192Lymphoma 102Lymphoma, Non-Hodgkin 90Leukemia, Myeloid, Acute 89Precursor Cell Lymphoblastic Leukemia-Lymphoma 81Myelodysplastic Syndromes 81Hodgkin Disease 67Leukemia 66Neoplasms, Plasma Cell 65Lymphoma, Large B-Cell, Diffuse 59Leukemia, Lymphocytic, Chronic, B-Cell 58Lymphoma, Mantle-Cell 52Lymphoma, Follicular 49Burkitt Lymphoma 39Lymphoma, Large-Cell, Immunoblastic 35Lymphoma, B-Cell, Marginal Zone 34Myeloproliferative Disorders 30Recurrence 28Hematologic Neoplasms 28Neuroblastoma 25Leukemia, Myelogenous, Chronic, BCR-ABL Positive 25Leukemia, Myeloid, Accelerated Phase 24Graft vs Host Disease 23Leukemia, Myelomonocytic, Chronic 22Leukemia, Myeloid, Chronic-Phase 22Congenital Abnormalities 21Immunoglobulin Light-chain Amyloidosis 20Dendritic Cell Sarcoma, Interdigitating 19Primary Myelofibrosis 18Waldenstrom Macroglobulinemia 17

Interventions

Doxorubicin 8Cyclophosphamide 8Vincristine 7Prednisone 7Etoposide 6Brentuximab Vedotin 4prednylidene 3etoposide phosphate 3Bortezomib 3pembrolizumab 2deltacortene 2Vorinostat 2Prednisolone 2Ifosfamide 2tazemetostat 1romidepsin 1pirarubicin 1duvelisib 1Salvia hispanica seed extract 1Peripheral Blood Stem Cell Transplantation 1Panobinostat 1Nivolumab 1Methylprednisolone 1Methotrexate 1Melphalan 1Lenalidomide 1Lactones 1Gemcitabine 1Everolimus 1Diet, Gluten-Free 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Enteropathy-Associated T-Cell Lymphoma × Melphalan × Clear all
NCT06692452 2026-04-01

Tazemetostat Plus CHOP in 1L T-cell Lymphoma

Dana-Farber Cancer Institute

Phase 2 Withdrawn
Lymphoid

Immunoblastic Lymphadenopathy, Lymphoma, Lymphoma, T-Cell, Peripheral, Enteropathy-Associated T-Cell Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡